GNTA Key Statistics, Chart & Performance
The current stock price of GNTA is 1.3 USD. In the past month the price decreased by -6.47%. In the past year, price decreased by -65.43%.
GNTA Technical Analysis
GNTA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to GNTA. While GNTA seems to be doing ok healthwise, there are quite some concerns on its profitability.
GNTA Financial Highlights
Over the last trailing twelve months GNTA reported a non-GAAP Earnings per Share(EPS) of -0.44. The EPS increased by 3.88% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -40.37% | ||
| ROE | -71.82% | ||
| Debt/Equity | 0.62 |
GNTA Forecast & Estimates
7 analysts have analysed GNTA and the average price target is 21.42 USD. This implies a price increase of 1547.69% is expected in the next year compared to the current price of 1.3.
GNTA Ownership
GNTA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 22.68 | 378.84B | ||
| AMGN | AMGEN INC | 15.11 | 177.92B | ||
| GILD | GILEAD SCIENCES INC | 15.25 | 154.97B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.42 | 111.98B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.29 | 77.04B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 704.45 | 47.46B | ||
| INSM | INSMED INC | N/A | 34.43B | ||
| NTRA | NATERA INC | N/A | 31.91B | ||
| BIIB | BIOGEN INC | 9.82 | 24.12B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 23.25B | ||
| INCY | INCYTE CORP | 16.54 | 20.85B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.62 | 20.02B |
Related stock screener links
About GNTA
Company Profile
Genenta Science SpA is an early-stage company, which engages in the development of first-in-class cell and gene cancer therapies. The company is headquartered in Milan, Milano and currently employs 13 full-time employees. The company went IPO on 2021-12-15. The firm focuses on the development of lentivirus-based gene and cell therapies in cancer. The company uses gene-based cytokine delivery to activate the immune system within the tumor providing the anti-tumor response. The firm not only operates locally but also is present in global markets, including the United States.
Company Info
GENENTA SCIENCE SPA - ADR
Via Olgettina 58
Milan MILANO IT
Employees: 13
GENENTA SCIENCE SPA - ADR / GNTA FAQ
Can you describe the business of GENENTA SCIENCE SPA - ADR?
Genenta Science SpA is an early-stage company, which engages in the development of first-in-class cell and gene cancer therapies. The company is headquartered in Milan, Milano and currently employs 13 full-time employees. The company went IPO on 2021-12-15. The firm focuses on the development of lentivirus-based gene and cell therapies in cancer. The company uses gene-based cytokine delivery to activate the immune system within the tumor providing the anti-tumor response. The firm not only operates locally but also is present in global markets, including the United States.
Can you provide the latest stock price for GENENTA SCIENCE SPA - ADR?
The current stock price of GNTA is 1.3 USD. The price decreased by -5.8% in the last trading session.
What is the dividend status of GENENTA SCIENCE SPA - ADR?
GNTA does not pay a dividend.
What is the ChartMill rating of GENENTA SCIENCE SPA - ADR stock?
GNTA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What sector and industry does GENENTA SCIENCE SPA - ADR belong to?
GENENTA SCIENCE SPA - ADR (GNTA) operates in the Health Care sector and the Biotechnology industry.
What is the ownership structure of GENENTA SCIENCE SPA - ADR (GNTA)?
You can find the ownership structure of GENENTA SCIENCE SPA - ADR (GNTA) on the Ownership tab.
What is the outstanding short interest for GENENTA SCIENCE SPA - ADR?
The outstanding short interest for GENENTA SCIENCE SPA - ADR (GNTA) is 0.68% of its float.